ACE Report Cover
Subsidence and retroversion of femoral stem not affected by tobramycin-laden bone cement
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
Idioma
Download Download Download
Descarregar
Cite this Report Cite this Report Cite this Report
Citar
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ Favoritos
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
Idioma
Download Download Download
Descarregar
Cite this Report Cite this Report Cite this Report
Citar
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ Favoritos

ARTHROPLASTY

The effect of adding tobramycin to Simplex P cement on femoral stem micromotion as measured by radiostereometric analysis: a 2-year randomized controlled trial
Verified
This report has been verified by one or more authors of the original publication.

OrthoEvidence Journal (OE Journal) - ACE Report

OE Journal. 2013;1(12):91 Acta Orthop. 2012 Apr;83(2):115-20. doi: 10.3109/17453674.2011.652885. Epub 2012 Jan 17

Autores contribuintes

E Bohm M Petrak T Gascoyne T Turgeon

28 patients scheduled for total hip arthroplasty were randomized to receive cementing of components with simplex P cement or simplex T cement (which is simplex P cement with 1g tobramycin added by the manufacturer), to determine the effect of the antibiotic on aseptic component loosening. Radiostereometric analysis (RSA) of migration and rotation of the femoral stem component and clinical outcomes of Harris Hip and Western Ontario and McMaster Universities Arthritis Index (WOMAC) scores were examined over 2 years. The results indicated that there were no significant differences between groups at any time and demonstrated that simplex T cement did not adversely affect component loosening and functional outcomes in total hip arthroplasty over 2 years.


Detalhes do financiamento da publicação +
Financiamento:
Industry funded
Patrocinador:
Stryker Orthopaedics
Conflitos:
None disclosed

Risco de viés

8,5/10

Critérios de notificação

17/20

Índice de Fragilidade

N/A

Was the allocation sequence adequately generated?

Was allocation adequately concealed?

Blinding Treatment Providers: Was knowledge of the allocated interventions adequately prevented?

Blinding Outcome Assessors: Was knowledge of the allocated interventions adequately prevented?

Blinding Patients: Was knowledge of the allocated interventions adequately prevented?

Was loss to follow-up (missing outcome data) infrequent?

Are reports of the study free of suggestion of selective outcome reporting?

Were outcomes objective, patient-important and assessed in a manner to limit bias (ie. duplicate assessors, Independent assessors)?

Was the sample size sufficiently large to assure a balance of prognosis and sufficiently large number of outcome events?

Was investigator expertise/experience with both treatment and control techniques likely the same (ie.were criteria for surgeon participation/expertise provided)?

Sim = 1

Incerto = 0,5

Não relevante = 0

Não = 0

A Avaliação dos Critérios de Relato avalia a transparência com que os autores relatam as caraterísticas metodológicas e do ensaio na publicação. A avaliação está dividida em cinco categorias que são apresentadas de seguida.

4/4

Randomization

4/4

Outcome Measurements

3/4

Inclusion / Exclusion

3/4

Therapy Description

3/4

Statistics

Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65

O Índice de Fragilidade é uma ferramenta que auxilia na interpretação de achados significativos, fornecendo uma medida de força para um resultado. O Índice de Fragilidade representa o número de eventos consecutivos que precisam de ser adicionados a um resultado dicotómico para que o resultado deixe de ser significativo. Um número pequeno representa um resultado mais fraco e um número grande representa um resultado mais forte.

Porque é que este estudo era necessário agora?

Since the introduction of antibiotic-laden bone cement, laboratory testing has shown that a 1 gram to 20 gram ratio of antibiotic to bone cement powder has a negligible effect on the mechanical strength and fixation properties of bone cement. However, the appropriateness of the laboratory testing has been questioned, since regulatory standards require testing after 24 hours, which does not necessarily translate into long-term clinical success. Furthermore, no study has directly examined antibiotic additives to bone cement with the risk of aseptic loosening of components, indicating the need for this trial.

Qual era a principal questão de investigação?

Does Simplex T bone cement increase the risk of aseptic component loosening when measured after 2 years?

Caraterísticas do estudo +
População:
28 patients (30 hips) scheduled for primary total hip arthroplasty with Exeter femoral stems coupled with Trident acetabular cups (Stryker Orthopaedics). Direct lateral or posterior surgical approaches were performed. Tantalum markers were injected into greater trochanter, lesser trochanter, and femoral shaft for detection of migration using RSA (n=25 hips completed follow-up)
Intervenção:
Simplex T Group: Patients received cementing of components with tobramycin-laden Simplex P bone cement. (n=14)
Comparação:
Simplex P Group: Patients received cementing of components with Simplex P bone cement, with no antibiotic added by the manufacturer. (n=11)
Resultados:
Primary outcome was stem subsidence measured with RSA. Secondary outcomes were stem rotation/retroversion (assessed with RSA) and functional scores (assessed with Harris Hip Score and Western Ontario and McMaster Universities Arthritis Index (WOMAC))
Métodos:
RCT, Triple blind
Tempo:
Follow-up was conducted at 6 weeks (RSA exclusive), 6 months, 1, and 2 years.

Quais foram os resultados importantes?

  • Mean subsidence after 2 years did not significantly differ between groups, with translation of 0.71mm (SD 0.30) in the control group (Simplex P) and 0.77mm (SD 0.36) in tobramycin-laden group (Simplex T) (Difference 0.06, 95%CI -0.21 to 0.34, p=0.6). Component translation did not significantly differ between groups at the 6 month (p=0.9) or 1 year (p=0.7) follow-up periods, either.
  • The two groups did not significantly differ in mean retroversion of component after 2 years: 0.60 degrees (SD 0.72) for Simplex P group versus 0.84 degrees (0.93) for Simplex T group (Difference -0.24, 95%CI -0.94 to 0.47, p=0.5). Progression of retroversion at 6 months (p=0.6) and 1 year (p=0.6) follow-up were not significantly different between groups.
  • Differences were not significant between groups in functional outcomes of Harris Hip Scores and WOMAC Scores at any point in the study. (all p-values>0.2).
  • Cumulative migrations in the second year indicated substantial distal and moderate posterior migration of the stem, which was similar in both groups.
De que é que me devo lembrar mais?

The addition of tobramycin to Simplex P bone cement had no effect on the subsidence and retroversion of the femoral stem, as well Harris hip and WOMAC functional scores, when compared to bone cement without antibiotic after 2 years.

Como é que isto afectará o tratamento dos meus doentes?

The results of this trial indicated that antibiotic-laden bone cement is a safe method of cementing in total hip arthroplasty as it did not affect the subsidence and retroversion of the femoral stem component after 2 years. However, further studies with longer follow-up and larger sample sizes are necessary to assess the long-term results.

AVISO LEGAL

O conteúdo desta página destina-se apenas a fins informativos e não pretende substituir o aconselhamento, diagnóstico ou tratamento médico profissional. Se necessitar de tratamento médico, procure sempre o conselho do seu médico ou dirija-se ao serviço de urgência mais próximo. As opiniões, crenças e pontos de vista expressos pelos indivíduos no conteúdo encontrado nesta página não reflectem as opiniões, crenças e pontos de vista da OrthoEvidence.

0 de 4 artigos mensais GRATUITOS desbloqueados
Atingiu o seu limite de 4 visualizações de artigos gratuitos este mês

Aceda à OrthoEvidence por apenas $1,99 por semana.

Mantenha-se ligado às últimas evidências. Cancele a qualquer altura.
  • Avaliações críticas dos mais recentes ensaios clínicos aleatórios de alto impacto e revisões sistemáticas em ortopedia
  • Acesso ao conteúdo do podcast OrthoEvidence, incluindo colaborações com o Journal of Bone and Joint Surgery, entrevistas com cirurgiões reconhecidos internacionalmente e discussões em mesa redonda sobre notícias e tópicos ortopédicos
  • Subscrição do The Pulse, um boletim informativo duas vezes por semana baseado em evidências, concebido para o ajudar a tomar melhores decisões clínicas
Upgrade
Close Dialog
Bem-vindo de volta!
Esqueceu-se da palavra-passe?
Comece hoje o seu teste GRATUITO!

A sua conta será afiliada a
e inclui acesso gratuito ao OrthoEvidence


OU
Esqueceu-se da palavra-passe?

OU
Verifique o seu e-mail

Se existir uma conta com o endereço de e-mail fornecido, ser-lhe-á enviado um e-mail de reposição da palavra-passe. Se não vir uma mensagem de correio eletrónico, verifique a sua pasta de spam ou de lixo eletrónico.

Para obter mais assistência, contacte a nossa equipa de apoio.

Inicie sessão para ativar esta funcionalidade

Para aceder a esta funcionalidade, tem de iniciar sessão numa conta OrthoEvidence ativa. Inicie a sessão ou crie uma conta de avaliação GRATUITA.

Traduzir o Relatório ACE

A OrthoEvidence utiliza um serviço de tradução de terceiros para tornar o conteúdo acessível em vários idiomas. Tenha em atenção que, embora sejam feitos todos os esforços para garantir a exatidão, as traduções podem nem sempre ser perfeitas.

Como citar isto ACE Report

OrthoEvidence. Subsidence and retroversion of femoral stem not affected by tobramycin-laden bone cement. OE Journal. 2013;1(12):91. Available from: https://myorthoevidence.com/AceReport/Show/subsidence-and-retroversion-of-femoral-stem-not-affected-by-tobramycin-laden-bone-cement

Copie a citação
Inicie sessão para ativar esta funcionalidade

Para aceder a esta funcionalidade, tem de iniciar sessão numa conta OrthoEvidence ativa. Inicie a sessão ou crie uma conta de avaliação GRATUITA.

Funcionalidade de Membro Premium

Para aceder a esta funcionalidade, tem de ter sessão iniciada numa conta Premium da OrthoEvidence.

Partilhe isto ACE Report